Crossmark

Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness

Crossref DOI link: https://doi.org/10.1186/s12885-019-5909-5

Published Online: 2019-07-15

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bencsikova, Beatrix

Budinska, Eva

Selingerova, Iveta

Pilatova, Katerina

Fedorova, Lenka

Greplova, Kristina

Nenutil, Rudolf

Valik, Dalibor

Obermannova, Radka

Sheard, Michael A.

Zdrazilova-Dubska, Lenka https://orcid.org/0000-0001-6397-0993
Funding

Funding for this research was provided by:

Ministerstvo Zdravotnictví Ceské Republiky (AZV 16-31966A)

Ministerstvo Zdravotnictví Ceské Republiky (AZV 16-31966A, DRO 00209805, DRO 00209805, AZV 16-31966A, DRO 00209805, AZV 16-31966A)

Ministerstvo Školství, Mládeže a Tělovýchovy (LO1413, LM2015089, LM2015089, LO1413)
License Information

Text and Data Mining valid from 2019-07-15

Version of Record valid from 2019-07-15
More Information

Article History

Received: 8 October 2018

Accepted: 8 July 2019

First Online: 15 July 2019

Ethics approval and consent to participate

: The study was performed in compliance with the Declaration of Helsinki, was approved by the Ethics Committee of Masaryk Memorial Cancer Institute (MMCI, Brno, Czech Republic; reference number MOU/EK/131210) and written informed consent was obtained from all patients.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below